Nisa Investment Advisors LLC Sells 921 Shares of LivaNova PLC (NASDAQ:LIVN)

Nisa Investment Advisors LLC decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 64.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 516 shares of the company’s stock after selling 921 shares during the quarter. Nisa Investment Advisors LLC’s holdings in LivaNova were worth $27,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of LIVN. Primecap Management Co. CA grew its position in LivaNova by 7.3% in the 3rd quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock valued at $305,930,000 after acquiring an additional 395,940 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of LivaNova by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,770,277 shares of the company’s stock worth $93,612,000 after purchasing an additional 100,133 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in LivaNova by 96.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock valued at $48,471,000 after buying an additional 449,136 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of LivaNova by 31.1% during the third quarter. Loomis Sayles & Co. L P now owns 879,740 shares of the company’s stock worth $46,520,000 after acquiring an additional 208,755 shares during the period. Finally, Barclays PLC raised its stake in shares of LivaNova by 15.9% during the third quarter. Barclays PLC now owns 851,870 shares of the company’s stock valued at $45,047,000 after acquiring an additional 116,842 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Stock Up 3.2 %

NASDAQ:LIVN opened at $54.01 on Tuesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.51 and a current ratio of 2.95. The stock has a market capitalization of $2.91 billion, a P/E ratio of 168.79 and a beta of 0.89. The company’s 50-day simple moving average is $53.65 and its 200-day simple moving average is $50.54. LivaNova PLC has a fifty-two week low of $42.75 and a fifty-two week high of $59.86.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s revenue for the quarter was up 12.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.81 earnings per share. On average, equities analysts anticipate that LivaNova PLC will post 3.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Mizuho restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Wednesday, March 27th. Needham & Company LLC restated a “buy” rating and issued a $72.00 price objective on shares of LivaNova in a report on Wednesday, March 20th. Barclays increased their target price on shares of LivaNova from $57.00 to $61.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Robert W. Baird boosted their price target on shares of LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, February 22nd. Finally, StockNews.com lowered shares of LivaNova from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, LivaNova currently has an average rating of “Hold” and a consensus price target of $64.40.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.